Baxter Healthcare

With a history spanning more than 85 years in parenteral products, Baxter’s BioPharma Solutions (BPS) division collaborates with pharmaceutical firms to assist in achieving their commercialization goals for their drugs. BPS stands as a prominent contract manufacturing organization (CMO) that specializes in the production of specialized sterile injectables, aiming to address both traditional and complex sterile challenges. The state-of-the-art facilities, which have received awards, are situated in different primary locations. The Bloomington, Indiana, USA facility is renowned for its expertise in sterile contract manufacturing and offers form/fill/finish services and solutions for injectables tailored to meet conventional sterile manufacturing challenges. On the other hand, the Halle/Westfalen, Germany facility has over six decades of experience and is acknowledged as a top-tier manufacturer of oncology products and other sophisticated compounds. BPS is well-equipped to cater to pharmaceutical requirements with a wide range of capabilities for sterile fill/finish production, and its reputation is established on delivering high-quality products in a cGMP environment to its clients. The division offers delivery systems such as prefilled syringes, liquid/lyophilized vials, diluents for reconstitution, powder-filled vials, and sterile crystallization. Additionally, BPS covers diverse drug categories including small molecules, biologics, vaccines, cytotoxics, highly potent compounds, and antibody-drug conjugates (ADCs). From the initial formulation and development stages to the commercial launch, BPS provides comprehensive and tailored support services to navigate the complexities of the market and assist in maximizing the potential value of the drug molecule. Whether encountering formulation challenges, clinical supply obstacles, fluctuations in market demands, concerns regarding risk mitigation, or challenges related to patent expiry, BPS offers adaptable and customized solutions to aid in achieving commercialization objectives.

Products & Services

0.9% Sodium Chloride Diluent, USP

Anti-Protein C Affinity Matrix

Bacteriostatic Water For Injection USP

Belantamab Mafodotin

Brentuximab Vedotin

Sites

Country

Singapore

Country

United States of America